New ALTG Study ILLUMINATE

Feasibility is open for the ILLUMINATE Study (ALTG 16/009) which is a phase 2 trial of durvalumab and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on epidermal growth factor receptor (EGFR) mutation Tyrosine Kinase Inhibitors (TKIs). The purpose of the study is to test the effectiveness of a new treatment strategy that combines immunotherapy together with chemotherapy for patients with epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC). Please contact altg@lungfoundation.com.au for more information.

Complete the survey.

Upcoming Events
  1. ALTG closed SAC and MAC meetings

    May 1 @ 8:00 am - 5:00 pm
  2. 6th ALTG Lung Cancer Preceptorship

    October 23 @ 10:00 am - October 24 @ 3:30 pm
  3. ALTG open MAC and SAC meetings

    November 20